TScan Therapeutics Inc. (Nasdaq: TCRX) is eliminating approximately 75% of its workforce and pausing further enrollment in its Phase 3 ALLOHA-2 trial because it does not have sufficient capital to complete the study.
The company announced the strategic reorganization on September 2. TScan will redirect its resources toward two preclinical in-vivo T-cell receptor-engineered T-cell therapy candidates for solid tumors.
The candidates target PRAME and MAGE-A4, proteins expressed by several tumor types. TScan expects to present preclinical findings during the first quarter of 2027, submit its first investigational new drug application in the third quarter and begin Phase 1 development in the fourth quarter of 2027.
The company believes its in-vivo approach could generate engineered T cells inside the body, potentially reducing the manufacturing costs and delays associated with conventional patient-specific cell therapy. Those potential benefits remain unproven because the candidates have not entered human testing.
TScan is pausing enrollment in ALLOHA-2 despite reporting updated findings from an earlier Phase 1 cohort of TSC-101. All 13 patients currently being tracked showed complete donor chimerism, a measure of how completely donor blood-forming cells have replaced the recipient’s original cells following transplantation.
The cohort is small, and two patients who had previously relapsed converted to complete donor chimerism after receiving another TSC-101 infusion, additional targeted treatments or both. The company will continue following those 13 patients and seven patients already enrolled in the Phase 3 treatment arm. Updated findings are expected during the fourth quarter of 2026 and second quarter of 2027.
CEO Gavin MacBeath said TScan had “made the difficult decision to allocate our resources to programs we believe better allow us to create value.”
TScan plans to seek partners for its hematologic-cancer and autoimmune programs. A partnership could allow TSC-101 development to resume, but no agreement has been announced.
The restructuring is expected to produce cumulative savings of approximately US$55 million through the end of 2027. TScan anticipates about US$4.1 million in employee-related charges and expects to substantially complete the reorganization by the end of 2026. The company is also eliminating its internal manufacturing organization and reducing its research footprint. Its chief financial officer and chief medical officer left as part of the changes.
TScan reported US$100.2 million in cash and cash equivalents as of June 30, excluding US$5 million in restricted cash. It recorded a first-half net loss of US$59 million and used US$51.8 million in operating cash. Its quarterly filing raised substantial doubt about its ability to continue as a going concern under its former operating plan. Management now expects the reduced spending plan to extend its runway into the fourth quarter of 2027.
Nasdaq has separately notified TScan that its shares do not satisfy the exchange’s US$1 minimum-bid requirement. The notice does not immediately affect the listing. TScan has until February 23, 2027 to regain compliance by maintaining a closing price of at least US$1 for ten consecutive trading days.
Upcoming Catalysts
- Updated TSC-101 Phase 1 data expected in the fourth quarter of 2026
- Completion of the restructuring by year-end
- Solid-tumor preclinical data expected in the first quarter of 2027
- Nasdaq’s February 23, 2027 compliance deadline
- Additional TSC-101 data expected in the second quarter of 2027
- A potential solid-tumor IND submission in the third quarter of 2027
- Possible partnerships for the hematologic-cancer and autoimmune programs
Sources
- TScan strategic-reorganization announcement — September 2, 2026
- TScan Form 8-K covering the restructuring and Nasdaq notice
- TScan Form 10-Q for the quarter ended June 30, 2026
- ALLOHA-2 clinical-trial record, NCT05473910
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, SEC filings and the federal clinical-trial registry. Securities discussed or referenced include TScan Therapeutics Inc. (Nasdaq: TCRX). Biotech Stocks Daily has not received compensation from TScan, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include TScan’s September 2, 2026 strategic-reorganization announcement, its related Form 8-K, its Form 10-Q for the quarter ended June 30, 2026 and the ClinicalTrials.gov record for ALLOHA-2. Clinical findings and development expectations originated primarily from TScan and have not been independently validated by Biotech Stocks Daily.
TScan’s product candidates remain investigational. The Phase 3 ALLOHA-2 trial has paused further enrollment, and the company may be unable to secure a partner or resume development. The reported TSC-101 findings involve a small number of patients, are not final trial results and do not establish regulatory approval or commercial viability. The solid-tumor candidates remain preclinical, and their proposed benefits have not been demonstrated in humans.
The expected restructuring savings, charges and cash runway are management estimates and may change. Workforce reductions could disrupt development, operations and employee retention. TScan has reported recurring losses, negative operating cash flow and substantial doubt regarding its ability to continue as a going concern under its previous operating plan. Additional financing could dilute existing shareholders.
TScan is not currently compliant with Nasdaq’s minimum-bid requirement. Although its shares remain listed, the company may ultimately face transfer or delisting proceedings if it cannot regain compliance. Financial information reflects the company’s position as of June 30, 2026 unless otherwise stated. No real-time securities prices are included.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
